Athlete Advisory: New prohibited stimulant replaces methylhexaneamine in supplement products

28 November 2014

ASADA cautions all Australian athletes subject to in-competition testing to be aware of the synthetic compound called 1,3-dimethylbutylamine (or DMBA), often listed on supplement labels as AMP Citrate.

Athletes testing positive to this stimulant in-competition may face a possible anti-doping rule violation.

ASADA understands DMBA use has never been studied in humans and has a structural similarity to the prohibited and potentially dangerous stimulant methylhexaneamine (DMAA). ASADA understands DMBA is being used to replace DMAA in many supplement formulations.

An overseas study (by Pieter A. Cohen, John C. Travis and Bastiaan J. Venhuis) found a range of supplement products containing DMBA, including:

ASADA has added DMBA to the check your substances database. DMBA is also known by many other pseudonyms including:

  • AMP Citrate;
  • 1,3-dimethylbutylamine;
  • Butylamine, 1,3-dimethyl-
  • 2-amino-4-methylpentane;
  • 2-Pentanamine;
  • 4-methyl-, 4-methylpentan-2-amine;

Supplements continue to be the source of preventable anti-doping rule violations both in Australia and overseas. More than half of the Australian athletes banned from sport in 2013 tested positive to a prohibited stimulant found within a supplement product.

It is important for athletes to understand the risks that these products may present to their health, career and reputation. Further information about supplements and the steps athletes can take to help minimise their risk is available on the ASADA website.